PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 3, 2025Circulation Journal0 citationsOpen Access

Real-World Safety and Effectiveness of Rivaroxaban in Cancer-Associated Venous Thromboembolism (PRIMECAST)　― A Prospective Multicenter Study ―

View Full Paper
YTYuichi TamuraMKMichinari KonoKHKosei Hasegawa

Key Points

  • VTE recurrence occurred in a small percentage of cancer patients, reflecting the effectiveness of rivaroxaban.
  • The study reports a low incidence of worsening VTE among patients across multiple centers in Japan.
  • This prospective multicenter study assessed the safety of rivaroxaban in the cancer-VTE population.
  • Findings imply that rivaroxaban may be a reliable option for managing venous thromboembolism in cancer patients.

Abstract

VTE recurrence/worsening occurred in only a small percentage of Japanese cancer-VTE patients treated with rivaroxaban.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tamura et al. (2025) studied this question.

synapsesocial.com/papers/694025912d562116f28fe92fhttps://doi.org/10.1253/circj.cj-25-0541
Ask AI
Helpful
Bookmark
Share
View Full Paper